Where Trackless Terrain Once Challenged Biomarker...
Where Does Your Region Stack Up...
GEN’s Expert Panel Reviews Filtration’s Triumphs,...
More Genomes Are Going Under the...
For full access to this article login to GEN Select now.
Industry cost-cutting and fewer physicians participating in clinical trials are among the hurdles to cancer R&D listed in a recent report. [© michaeljung - Fotolia.com]
Just 2% to 5% of adult patients now enroll in U.S. cancer trials, according to estimates offered over the past 15 years—a distressingly ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?
Be sure to add [email protected]
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2016 Genetic Engineering & Biotechnology News All Rights Reserved